HealthDay News — Primary human papillomavirus (HPV) screening intervals could be extended, with the risk for cervical precancer or worse (CIN2+) 8 years after negative HPV screening comparable to risk after 3 years in cytology cohorts, according to a study published online in Cancer Epidemiology, Biomarkers & Prevention.
Anna Gottschlich, PhD, MPH, from the BC Women’s Hospital and Health Services in Vancouver, British Columbia, Canada, and colleagues conducted a longitudinal cohort study involving women and individuals with a cervix (WIC) who received 1 to 2 negative HPV screens (5546 in the HPV1 cohort; 6624 in the HPV2 cohort) and WIC with 1 to 2 normal cytology results (782,297 in the BCS1 cohort; 673,778 in the BCS2 cohort). Participants were followed for 14 years.
The researchers found that after 8 years, the cumulative risks for CIN2+ were 3.2 and 2.7 per 1000 in HPV1 and HPV2, respectively. This was comparable to the cytology cohort risk after 3 years (3.3 and 2.5 per 1000 in BCS1 and BCS2, respectively). After 10 years, the cumulative risk for CIN2+ was low in the HPV cohorts (4.7 and 3.9 per 1000 in HPV1 and HPV2, respectively).
“These findings should provide assurance that the 5-year interval recommended for HPV screening is even safer than the 3-year interval for cytology screening,” Gottschlich said in a statement.
Two authors disclosed ties to the pharmaceutical industry; one has a patent registered on DNA methylation markers for early detection of cervical cancer.
Abstract/Full Text (subscription or payment may be required)
 "BCCI want Test specialists to play domestic cricket; Rohit, Virat, Bumrah to be exceptions")
